Abstract 3203: Honokiol inhibits growth and migration of renal cell carcinoma

Abstract

Renal cell carcinoma (RCC) is a common urological cancer worldwide and is known to the high risk of recurrence and metastasis. Approximately 70% of patients with RCC will develop recurrence after surgical resection, and 25%-30% of patients will eventually develop progression to distant metastasis. Honokiol is a small-molecule polyphenol isolated from the genus Magnolia, which has been shown to be a potential anticancer agent in multiple facets of signal transduction. Here we demonstrate that honokiol inhibits proliferation of RCC cells 786-0 and A498 without affecting cell viability. Moreover, honokiol also significantly inhibited migration of 786-0 cells in a dose-dependent manner. DNA microarray analysis showed that honokiol regulated expression of many genes related to human tumor metastasis in 786-0 cells. Real time PCR analysis confirmed that the expression of metastasis suppressor KISS1 and its receptor, KISS1R, were upregulated in 786-0 cells after treatment with honokiol. In addition, the shape changes and excessive formation of actin stress fibers were identified in 786-0 cells treated with honokiol. This phenomenon disappeared when treated cells with the pharmacological Rho-kinase inhibitor Y-27632 and honokiol. This inhibition can also be identified in 786-0 cells treated with Y-27632 only. Our present results demonstrated that honokiol could inhibit the growth and migration of RCC, which is likely to be regulated by the Rho and Rho-Associated Kinase (ROCK) pathway. In conclusion, honokiol is a biologically active natural compound which can be considered for the alternative treatment of RCC. The investigation of detailed mechanisms and molecular targets are in progress. Citation Format: Shujie Cheng, Matt Welty, Isaac Eliaz, Victor Castillo, Daniel Sliva. Honokiol inhibits growth and migration of renal cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3203. doi:10.1158/1538-7445.AM2014-3203

Enhancing the anti-glioma therapy of doxorubicin by honokiol with biodegradable self-assembling micelles through multiple evaluations

“…Honokiol (HK: Fig. 1A ) is a bio-active component of the bark of the Chinese traditional herb Magnolia officinals 8 . Previous studies have demonstrated the variety of pharmacological effects of HK, including anti-oxidative, anti-depressant, and anti-inflammatory effects 9 10 11 .…”